About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/16/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/16/2021.

GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose

Clinicaltrials.gov identifier NCT03943875

Recruitment Status Recruiting

First Posted May 9, 2019

Last update posted July 30, 2020

Study Description

Brief summary:

We are evaluating whether 15-26 year old males and females need a 3rd dose of the human papillomavirus (HPV) vaccine, or whether 2 doses provide similar protection as 3 doses from the 9 types of HPV that it protects against.

  • Condition or Disease:Immunization
    Efficacy
    Human Papilloma Virus
  • Intervention/Treatment: Biological: 9-valent HPV vaccine, 2 dose efficacy
    Biological: 9-valent HPV vaccine, 3 doses standard timing
  • Phase: Phase 4
Detailed Description

The investigators are studying an amended dosing regimen of an approved drug (Gardasil 9) in the population for which it is approved (vaccine is approved for ages 9-45 years and participants in this study will be 15-26 years of age.) The purpose of the study is to examine a delayed dosing schedule. The current recommendation is to administer the vaccine in 3 doses (administered at 0, 1-2 months and 6 months) to those 15-26 years of age but only 2 doses (0 and 6 months) if given at 9-14 years of age. The investigators will conduct a randomized study to determine if 2 doses will elicit an immune response similar to the standard 3 doses in those 15-26 years of age. Participants in the study group will receive 2 doses of Gardasil 9 at 0 and 6 months. Participants in the control group will receive 3 doses of Gardasil 9 at 0, 1-2 months and 6 months. All participants (Target Accrual n=512) will have 5 mLs of blood drawn at 0, 7, and 12 months. Following the 12 month blood draw, participants randomized to 2-doses will receive the 3rd dose. Potential participants will be recruited in the University of Texas Medical Branch (UTMB) clinics where providers have given the PI permission to directly contact patients. The investigators will also display signs and use email announcements at UTMB and other college campuses and will advertise the study online or by mail. The investigators will call UTMB patients if their provider gave permission to contact the patient, or if the patients gave prior consent to contact through the UTMB system. Potential participants (and their parents, if under 18 years of age) will be screened with inclusion/exclusion criteria. Eligible and interested parents and patients will sign informed written consent. Patients under 18 years of age will sign written assent. At the initial visit, eligible, consented participants will have their blood drawn, be randomized into either the study or control group, and receive a dose of the HPV vaccine. Participants will be re-screened against the inclusion/exclusion criteria at subsequent visits. All participants will receive compensation administered through a ClinCard following each of the 3 blood draws.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 512 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Other
  • Official Title: GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose
  • Actual Study Start Date: June 2019
  • Estimated Primary Completion Date: February 2022
  • Estimated Study Completion Date: February 2023
Arms and interventions
Arm Intervention/treatment
Experimental: Females, 2 dose with delayed 3rd dose
Two doses of the 9-valent HPV vaccine to be administered to the experimental group (15-26 years of age) at 0 and 6 months. Additional HPV vaccine dose will be offered after final blood draw at 12 months.
Biological: 9-valent HPV vaccine, 2 dose efficacy
Evaluate the efficacy of 2 doses of the HPV vaccine across a 12 month period following the 1st dose among 15-26 year old males and females.
Experimental: Males, 2 dose with delayed 3rd dose
Two doses of the 9-valent HPV vaccine to be administered to the experimental group (15-26 years of age) at 0 and 6 months. Additional HPV vaccine dose will be offered after final blood draw at 12 months.
Biological: 9-valent HPV vaccine, 2 dose efficacy
Evaluate the efficacy of 2 doses of the HPV vaccine across a 12 month period following the 1st dose among 15-26 year old males and females.
Active Comparator: Females, 3 dose standard
Three doses of the 9-valent HPV vaccine to be administered to the comparison group (15-26 years of age) at 0, 2, and 6 months.
Biological: 9-valent HPV vaccine, 3 doses standard timing
Will be comparison group for 2 dose efficacy group.
Active Comparator: Males, 3 dose standard
Three doses of the 9-valent HPV vaccine to be administered to the comparison group (15-26 years of age) at 0, 2, and 6 months.
Biological: 9-valent HPV vaccine, 3 doses standard timing
Will be comparison group for 2 dose efficacy group.
Outcome Measures
  • Primary Outcome Measures: 1. Short-term human papillomavirus (HPV) type-specific antibody response for type HPV-6 [ Time Frame: 7 months ]
    Yes/No for seroconversion, defined as changing from seronegative (no detectable antibodies) to seropositive (antibodies at or exceeding natural immunity levels) to HPV type 6, measured as number of participants.
  • 2. Short-term HPV type-specific antibody response for type HPV-11 [ Time Frame: 7 months ]
    Yes/No for seroconversion, defined as changing from seronegative (no detectable antibodies) to seropositive (antibodies at or exceeding natural immunity levels) to HPV type 11, measured as number of participants.
  • 3. Short-term HPV type-specific antibody response for type HPV-16 [ Time Frame: 7 months ]
    Yes/No for seroconversion, defined as changing from seronegative (no detectable antibodies) to seropositive (antibodies at or exceeding natural immunity levels) to HPV type 16, measured as number of participants.
  • 4. Short-term HPV type-specific antibody response for type HPV-18 [ Time Frame: 7 months ]
    Yes/No for seroconversion, defined as changing from seronegative (no detectable antibodies) to seropositive (antibodies at or exceeding natural immunity levels) to HPV type 18, measured as number of participants.
  • 5. Short-term HPV type-specific antibody response for type HPV-31 [ Time Frame: 7 months ]
    Yes/No for seroconversion, defined as changing from seronegative (no detectable antibodies) to seropositive (antibodies at or exceeding natural immunity levels) to HPV type 31, measured as number of participants.
  • 6. Short-term HPV type-specific antibody response for type HPV-33 [ Time Frame: 7 months ]
    Yes/No for seroconversion, defined as changing from seronegative (no detectable antibodies) to seropositive (antibodies at or exceeding natural immunity levels) to HPV type 33, measured as number of participants.
  • 7. Short-term HPV type-specific antibody response for type HPV-45 [ Time Frame: 7 months ]
    Yes/No for seroconversion, defined as changing from seronegative (no detectable antibodies) to seropositive (antibodies at or exceeding natural immunity levels) to HPV type 45, measured as number of participants.
  • 8. Short-term HPV type-specific antibody response for type HPV-52 [ Time Frame: 7 months ]
    Yes/No for seroconversion, defined as changing from seronegative (no detectable antibodies) to seropositive (antibodies at or exceeding natural immunity levels) to HPV type 52, measured as number of participants.
  • 9. Short-term HPV type-specific antibody response for type HPV-58 [ Time Frame: 7 months ]
    Yes/No for seroconversion, defined as changing from seronegative (no detectable antibodies) to seropositive (antibodies at or exceeding natural immunity levels) to HPV type 58, measured as number of participants.
  • 10. HPV type-specific antibody response for type HPV-6 [ Time Frame: 12 months ]
    Yes/ No count, Number of patients with an antibody level at or above predetermined cutoff (natural immunity) for HPV type 6. Measured as number of participants.
  • 11. HPV type-specific antibody response for type HPV-11 [ Time Frame: 12 months ]
    Yes/ No count, Number of patients with an antibody level at or above predetermined cutoff (natural immunity) for HPV type 11. Measured as number of participants.
  • 12. HPV type-specific antibody response for type HPV-16 [ Time Frame: 12 months ]
    Yes/ No count, Number of patients with an antibody level at or above predetermined cutoff (natural immunity) for HPV type 16. Measured as number of participants.
  • 13. HPV type-specific antibody response for type HPV-18 [ Time Frame: 12 months ]
    Yes/ No count, Number of patients with an antibody level at or above predetermined cutoff (natural immunity) for HPV type 18. Measured as number of participants.
  • 14. HPV type-specific antibody response for type HPV-31 [ Time Frame: 12 months ]
    Yes/ No count, Number of patients with an antibody level at or above predetermined cutoff (natural immunity) for HPV type 31. Measured as number of participants.
  • 15. HPV type-specific antibody response for type HPV-33 [ Time Frame: 12 months ]
    Yes/ No count, Number of patients with an antibody level at or above predetermined cutoff (natural immunity) for HPV type 33. Measured as number of participants.
  • 16. HPV type-specific antibody response for type HPV-45 [ Time Frame: 12 months ]
    Yes/ No count, Number of patients with an antibody level at or above predetermined cutoff (natural immunity) for HPV type 45. Measured as number of participants.
  • 17. HPV type-specific antibody response for type HPV-52 [ Time Frame: 12 months ]
    Yes/ No count, Number of patients with an antibody level at or above predetermined cutoff (natural immunity) for HPV type 52. Measured as number of participants.
  • 18. HPV type-specific antibody response for type HPV-58 [ Time Frame: 12 months ]
    Yes/ No count, Number of patients with an antibody level at or above predetermined cutoff (natural immunity) for HPV type 58. Measured as number of participants.
Eligibility Criteria
  • Ages Eligible for Study: 15 to 26 Years (Child, Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: Yes
Criteria

Inclusion Criteria:

1. Males and females 15-26 years old.

2. Ability to give informed consent. All participants under 18 years of age must have the
informed consent of a parent and must assent to participation.

3. Has not received any prior doses of the HPV vaccine. We will ask the patient and
his/her parent (if <18) about prior vaccination and check the state registry (Immtrac), as well as the UTMB electronic medical record (if previously seen at UTMB), We will check with their primary care provider, if feasible, for patients who are not a previously established UTMB patient. 4. Identified source of funding for vaccine which may include Texas Vaccines for Children (VFC) program, Medicaid, the Children's Health Insurance Plan (CHIP), Texas Healthy Women program or other public or private health insurance. 5. Reliable telephone access. 6. Participant and parent/ guardian (if <18) can read and speak either English or Spanish. Exclusion Criteria: 1. For females, currently pregnant or plans to become pregnant or donate eggs in next 12 months. Sexually active females must report that they use regular birth control. All female subjects will be required to take a urine pregnancy test before each Gardasil 9 dose. Any subjects with positive tests will be disqualified from the study and advised to seek prenatal care. 2. History of 6 or more lifetime sexual partners. 3. History of any immunodeficiencies (HIV+, chemotherapy treatment, status splenectomy) or autoimmune disorders (lupus, thyroid disorder, psoriasis). 4. History of bleeding or platelet disorders such as hemophilia. 5. Currently taking medication which can suppress immune function including systemic corticosteroids, radiation therapy, cyclophosphamide, azathioprine, methotrexate, cyclosporine, leflunomid, TNF-alpha antagonists, monoclonal antibody therapies, or intravenous immunoglobulin treatment. 6. Known allergies to any components of the vaccine, including aluminum, yeast or Benzonase. 7. Febrile at ≥100°F in the 24 hours prior to vaccination. This will be reviewed before each Gardasil 9 dose. 8. Received any non-study inactive vaccines within the past 14 days or any live vaccines within the past 30 days. Those excluded for this reason will be re-screened under the same study number at a later date. 9. Plan to move out of the Galveston/Houston area in the 13 months following study entry.

Contacts and Locations
Contacts

Contact: Abbey B Berenson, MD, PhD 409-772-2417 abberens@utmb.edu

Contact: Christie K Shumate 409-747-5594 ckshumat@utmb.edu

Locations

United States, Texas
University of Texas Medical Branch
Galveston

Sponsors and Collaborators

The University of Texas Medical Branch, Galveston

Cancer Prevention Research Institute of Texas

Investigators

Principal Investigator: Abbey B Berenson, MD, PhD University of Texas

More Information
  • Responsible Party: The University of Texas Medical Branch, Galveston
  • ClinicalTrials.gov Identifier: NCT03943875 History of Changes
  • Other Study ID Numbers: 19-0058, RP190022
  • First Posted: May 9, 2019 Key Record Dates
  • Last Update Posted: July 30, 2020
  • Last Verified: July 2020
  • Studies a U.S. FDA-regulated Drug Product: Yes
  • Studies a U.S. FDA-regulated Device Product: No
  • Product Manufactured in and Exported from the U.S.: Yes
  • Keywords provided by The University of Texas Medical Branch, Galveston: HPV vaccination
    Gardasil 9
    vaccine efficacy
  • Additional relevant MeSH terms: Papilloma